28th Aug 2015 14:45
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES | |||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | ReNeuron Group plc | ||
2 Reason for the notification (please tick the appropriate box or boxes): | |||
An acquisition or disposal of voting rights | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||
An event changing the breakdown of voting rights | |||
Other (please specify): Change to notifiable interest following share issue. | √ | ||
3. Full name of person(s) subject to thenotification obligation: | Abingworth LLP Abingworth Bioventures VI LP Abingworth Bioequities Master Fund Limited | ||
4. Full name of shareholder(s) (if different from 3.): | State Street Nominees Limited (as nominee for Abingworth Bioventures VI LP).
Jefferies & Co Inc. (as nominee for Abingworth Bioequities Master Fund Limited).
| ||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 25 August 2015 | ||
6. Date on which issuer notified: | 28 August 2015 | ||
7. Threshold(s) that is/are crossed orreached: | Below 3% threshold - Abingworth LLP and Abingworth Bioequities Master Fund Limited. | ||
8. Notified details: Abingworth LLP | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||
GB00B0DZML60
| 94,400,000 | 94,400,000 | 2.99% | |||||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
94,400,000 | 2.99% | |||||||||||||||
8. Notified details: Abingworth Bioequities Master Fund Limited | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||
GB00B0DZML60
| 83,652,000 | 83,652,000 | 83,652,000 | 83,652,000 | 2.65% | |||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
83,652,000 | 2.65% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||
Abingworth Bioventures VI LP (which holds 10,748,000 shares in the company (0.34%)) and Abingworth Bioequities Master Fund Limited (which holds 83,652,000 shares in the company (2.65%)) are both managed by Abingworth LLP.
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | ||
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: | ||
14. Contact name: | John Heard | |
15. Contact telephone number: | 020 7534 1500 | |
Related Shares:
RENE.L